Creative Planning’s Eledon Pharmaceuticals ELDN Stock Holding History

Creative Planning’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-8	Closed	-$1K	–	2395
2017 Q2	$1K	Buy	+8	New	+$815	﹤0.01%	4427
2016 Q3	–	Sell	-20	Closed	-$18K	–	4608
2016 Q2	$18K	Hold	20	–	–	﹤0.01%	2865
2016 Q1	$19K	Hold	20	–	–	﹤0.01%	2783
2015 Q4	$29K	Hold	20	–	–	﹤0.01%	2567
2015 Q3	$34K	Buy	+20	New	+$41.2K	﹤0.01%	2325
2015 Q2	–	Sell	-20	Closed	-$37K	–	1631
2015 Q1	$37K	Hold	20	–	–	﹤0.01%	2230
2014 Q4	$49K	Hold	20	–	–	﹤0.01%	2015
2014 Q3	$50K	Buy	+20	New	+$56.8K	﹤0.01%	1922

Other funds holding ELDN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

LSC

Lyon Street Capital Sausalito, California $67M AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Creative Planning's ELDN Position: Q3 2017 in Review

Creative Planning sold out of Eledon Pharmaceuticals (ELDN) in Q3 2017, closing a stake of 8 shares — an estimated $1K sold.

Creative Planning first reported a position in ELDN in Q3 2014 and held it in 8 quarters. The position peaked at $50K in Q3 2014. 15 funds tracked by Wall St. Rank hold ELDN as of Q3 2017.

Creative Planning reported no remaining Eledon Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Creative Planning sold 8 Eledon Pharmaceuticals shares in Q3 2017, an estimated $1K.
Creative Planning first reported a position in Eledon Pharmaceuticals in Q3 2014 and held it in 8 quarters.
Creative Planning's Eledon Pharmaceuticals position peaked at $50K in Q3 2014.
15 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q3 2017.

Based on Creative Planning's 13F filing for Q3 2017, filed 17 Oct 2017.